gemcitabine has been researched along with gdc 0449 in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Jenks, S | 1 |
| Saif, MW; Sarris, EG; Syrigos, KN | 1 |
| Abel, EV; Balis, UG; Blau, JL; Craig, R; Greenson, JK; Griffith, KA; Khan, GN; Kim, EJ; Sahai, V; Simeone, DM; Takebe, N; Zalupski, MM | 1 |
| Bahary, N; Catenacci, DV; Cohen, D; de Sauvage, FJ; Henderson, L; Horiba, MN; Junttila, MR; Karrison, T; Kindler, HL; Kozloff, M; Kumar, P; Lenz, HJ; Marsh, R; Nattam, SR; Rajdev, L; Salgia, R; Sleckman, B; Stadler, WM; Stiff, P; Takebe, N; Wade, J; Wallace, J; Wang, X; Xu, P | 1 |
| Alvaro, D; Bragazzi, MC; Cardinale, V; Carpino, G; Costantini, D; De Rose, AM; Di Matteo, S; Fraveto, A; Gaudio, E; Giuliante, F; Grazi, GL; Lustri, AM; Napoletano, C; Nevi, L; Renzi, A; Semeraro, R | 1 |
| Dutta, R; Karaca, M; Mahato, RI; Ozsoy, Y | 1 |
| Ji, S; Liang, C; Liang, D; Meng, Q; Ni, Q; Qin, Y; Shi, S; Xu, J; Yu, X; Zhang, B | 1 |
| Borowicz, P; Confeld, M; Mallik, S; Quadir, M; Ray, P; Wang, T | 1 |
| Anders, R; Batukbhai, B; Begum, A; De Jesus-Acosta, A; de Wilde, RF; Laheru, DA; Maitra, A; McAllister, F; O'Dwyer, PJ; Rajeshkumar, NV; Ramanathan, RK; Rasheed, Z; Sahin, I; Sugar, EA; Von Hoff, DD; Yabuuchi, S; Zheng, L | 1 |
| Arora, S; Carter, JE; Gorman, GS; Khan, MA; Khushman, M; Patel, GK; Singh, AP; Singh, S; Srivastava, SK; Zubair, H | 1 |
1 review(s) available for gemcitabine and gdc 0449
| Article | Year |
|---|---|
Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?
Topics: Albumins; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronic Acid; Osteonectin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pyridines; Stromal Cells; Survival Analysis; Treatment Outcome | 2018 |
3 trial(s) available for gemcitabine and gdc 0449
| Article | Year |
|---|---|
Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Deoxycytidine; Female; Gemcitabine; Hedgehog Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Pyridines; Signal Transduction; Treatment Outcome | 2014 |
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hedgehog Proteins; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Mice; Middle Aged; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Pyridines; Signal Transduction; Treatment Outcome | 2015 |
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma.
Topics: Aged; Albumins; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Pyridines; Treatment Outcome | 2020 |
7 other study(ies) available for gemcitabine and gdc 0449
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
AACR highlights: promise for treating pancreatic cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Delayed Diagnosis; Deoxycytidine; Disease Progression; Gemcitabine; Genes, ras; Humans; Mice; Molecular Targeted Therapy; Mutation; Off-Label Use; Paclitaxel; Pancreatic Neoplasms; Pyridines; Signal Transduction; Transcription Factors; United States | 2011 |
Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Indoles; Niacinamide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Molecular Targeted Therapy; Mucins; Neoplasm Transplantation; Phthalazines; Pyridines | 2015 |
Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Topics: Adenocarcinoma; Anilides; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Dodecanol; Gemcitabine; Humans; Male; Mice; Mice, Nude; Micelles; Pancreatic Neoplasms; Polyethylene Glycols; Polymers; Propane; Pyridines; Signal Transduction | 2016 |
PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Hydrogen-Ion Concentration; Mice; Mice, Nude; Micelles; Nanoparticles; Pancreatic Neoplasms; Polycarboxylate Cement; Polyethylene Glycols; Polymers; Pyridines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
Topics: Anilides; Animals; Antimetabolites, Antineoplastic; Benzylamines; Cell Communication; Cell Survival; Coculture Techniques; Cyclams; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Hedgehog Proteins; Heterocyclic Compounds; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Pancreatic Stellate Cells; Pyridines; Reactive Oxygen Species; Receptors, CXCR4; RNA Interference; RNA, Small Interfering; Signal Transduction | 2020 |